Quadrant Capital Boosts Regeneron Pharmaceuticals Holdings

Investment firm increases stake in biotech company by 78% in Q3

Mar. 12, 2026 at 10:34am

Got story updates? Submit your updates here. ›

Quadrant Capital Group LLC, an investment management firm, boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 78% during the third quarter of 2025, according to a recent SEC filing. The firm now owns 3,568 shares of the biopharmaceutical company's stock, valued at $2,006,000 as of the end of the quarter.

Why it matters

Regeneron Pharmaceuticals is a major player in the biotech industry, known for its innovative drug discovery technologies and pipeline of biologic therapies. Institutional investor activity in the company's stock can provide insights into market sentiment and future growth prospects.

The details

According to the 13F filing, Quadrant Capital Group purchased an additional 1,564 shares of Regeneron Pharmaceuticals during the third quarter, increasing its total stake by 78%. The investment firm now holds 3,568 shares of the biopharmaceutical company, valued at $2,006,000 as of the end of the quarter.

  • Quadrant Capital Group LLC boosted its position in Regeneron Pharmaceuticals during the 3rd quarter of 2025.

The players

Quadrant Capital Group LLC

An investment management firm that has increased its stake in Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

Quadrant Capital Group's increased investment in Regeneron Pharmaceuticals suggests the firm sees growth potential in the biotech company's innovative drug pipeline and technology platform. This institutional activity could signal broader market confidence in Regeneron's future prospects.